MP-AzeFlu Allergen Chamber - Onset of Action Study
Status:
Completed
Trial end date:
2017-03-29
Target enrollment:
Participant gender:
Summary
This study is to assess the onset of action of fixed drug combination of azelastine
hydrochloride and fluticasone propionate nasal spray (MP-AzeFlu) in treating the nasal
symptoms of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an
Environmental Exposure Chamber (EEC).